Tags

Type your tag names separated by a space and hit enter

Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states.
Curr Mol Med. 2006 Sep; 6(6):677-84.CM

Abstract

The endogenous cannabinoid system has revealed potential avenues to treat many disease states. Medicinal indications of cannabinoid drugs including compounds that result in enhanced endocannabinoid responses (EER) have expanded markedly in recent years. The wide range of indications covers chemotherapy complications, tumor growth, addiction, pain, multiple sclerosis, glaucoma, inflammation, eating disorders, age-related neurodegenerative disorders, as well as epileptic seizures, traumatic brain injury, cerebral ischemia, and other excitotoxic insults. Indeed, a great effort has led to the discovery of agents that selectively activate the cannabinoid system or that enhance the endogenous pathways of cannabinergic signaling. The endocannabinoid system is comprised of three primary components: (i) cannabinoid receptors, (ii) endocannabinoid transport system, and (iii) hydrolysis enzymes that break down the endogenous ligands. Two known endocannabinoids, anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), are lipid molecules that are greatly elevated in response to a variety of pathological events. This increase in endocannabinoid levels is suggested to be part of an on-demand compensatory response. Furthermore, activation of signaling pathways mediated by the endogenous cannabinoid system promotes repair and cell survival. Similar cell maintenance effects are elicited by EER through inhibitors of the endocannabinoid deactivation processes (i.e., internalization and hydrolysis). The therapeutic potential of the endocannabinoid system has yet to be fully determined, and the number of medical maladies that may be treated will likely continue to grow. This review will underline studies that demonstrate medicinal applications for agents that influence the endocannabinoid system.

Authors+Show Affiliations

Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269-3092, USA. david.karanian@uconn.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17022737

Citation

Karanian, David A., and Ben A. Bahr. "Cannabinoid Drugs and Enhancement of Endocannabinoid Responses: Strategies for a Wide Array of Disease States." Current Molecular Medicine, vol. 6, no. 6, 2006, pp. 677-84.
Karanian DA, Bahr BA. Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states. Curr Mol Med. 2006;6(6):677-84.
Karanian, D. A., & Bahr, B. A. (2006). Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states. Current Molecular Medicine, 6(6), 677-84.
Karanian DA, Bahr BA. Cannabinoid Drugs and Enhancement of Endocannabinoid Responses: Strategies for a Wide Array of Disease States. Curr Mol Med. 2006;6(6):677-84. PubMed PMID: 17022737.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states. AU - Karanian,David A, AU - Bahr,Ben A, PY - 2006/10/7/pubmed PY - 2006/12/13/medline PY - 2006/10/7/entrez SP - 677 EP - 84 JF - Current molecular medicine JO - Curr. Mol. Med. VL - 6 IS - 6 N2 - The endogenous cannabinoid system has revealed potential avenues to treat many disease states. Medicinal indications of cannabinoid drugs including compounds that result in enhanced endocannabinoid responses (EER) have expanded markedly in recent years. The wide range of indications covers chemotherapy complications, tumor growth, addiction, pain, multiple sclerosis, glaucoma, inflammation, eating disorders, age-related neurodegenerative disorders, as well as epileptic seizures, traumatic brain injury, cerebral ischemia, and other excitotoxic insults. Indeed, a great effort has led to the discovery of agents that selectively activate the cannabinoid system or that enhance the endogenous pathways of cannabinergic signaling. The endocannabinoid system is comprised of three primary components: (i) cannabinoid receptors, (ii) endocannabinoid transport system, and (iii) hydrolysis enzymes that break down the endogenous ligands. Two known endocannabinoids, anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), are lipid molecules that are greatly elevated in response to a variety of pathological events. This increase in endocannabinoid levels is suggested to be part of an on-demand compensatory response. Furthermore, activation of signaling pathways mediated by the endogenous cannabinoid system promotes repair and cell survival. Similar cell maintenance effects are elicited by EER through inhibitors of the endocannabinoid deactivation processes (i.e., internalization and hydrolysis). The therapeutic potential of the endocannabinoid system has yet to be fully determined, and the number of medical maladies that may be treated will likely continue to grow. This review will underline studies that demonstrate medicinal applications for agents that influence the endocannabinoid system. SN - 1566-5240 UR - https://www.unboundmedicine.com/medline/citation/17022737/Cannabinoid_drugs_and_enhancement_of_endocannabinoid_responses:_strategies_for_a_wide_array_of_disease_states_ L2 - http://www.eurekaselect.com/57713/article DB - PRIME DP - Unbound Medicine ER -